To boost research in America, Congress needs to renew a deal under which drugmakers payfees to regulators for reviewing new treatments.
要鼓励抗生素的研发,美国国会应恢复监管机构审查新药物疗效,制药商付费的协议。
The mammoth bill now before congressmen also includes measures to encourage the searchfor new antibiotics.
现在,摆在国会议员们面前内容繁多的议案中还包括鼓励新抗生素研发的一系列措施。
It would extend antibiotics patents by five years, and let some treatments forlife-threatening diseases be marketed before the final stage of clinical trials, therebyreducing their development costs.
如果该议案通过,那抗生素的专利权期限将延长五年,而且一些可治疗危及生命的疾病的抗生素在临床试验的最后阶段之前可投放市场,以减少它们的开发成本。
Kevin Outterson of Boston University says the government might provide an even biggerboost by paying more for new antibiotics,
波士顿大学的凯文奥特森认为政府可能会进一步刺激抗生素的研发,高价购买新抗生素,
but politicians are strongly allergic to spending more on health.
不过政治家们对于增加医疗健康开支都非常非常敏感。
【2015考研英语阅读制药商和抗生素】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30